Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

British Journal of Haematology

Volumn 155, Issue 2, 2011, Pages 182-189

  Becker, Pamela S ^a   Kantarjian, Hagop M ^b   Appelbaum, Frederick R ^a,c   Petersdorf, Stephen H ^a,c   Storer, Barry ^c   Pierce, Sherry ^b   Shan, Jianqin ^b   Hendrie, Paul C ^a   Pagel, John M ^a,c   Shustov, Andrei R ^a,c   Stirewalt, Derek L ^a,c   Faderl, Stephan ^b   Harrington, Elizabeth ^c   Estey, Elihu H ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Clinical trial phase 1; Clinical trial phase 2; Multivariate analysis; Remission induction; Salvage therapy

Indexed keywords

CLOFARABINE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; KIDNEY DISEASE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NEUROPATHY; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SIDE EFFECT; SKIN DISEASE; THROMBOCYTE COUNT; TUMOR LYSIS SYNDROME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG-INDUCED LIVER INJURY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFECTION; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RISK; SALVAGE THERAPY; YOUNG ADULT;

EID: 80053561103     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08831.x     Document Type: Article

References (34)

1. Bashey, A., Liu, L., Ihasz, A., Medina, B., Corringham, S., Keese, K., Carrier, E., Castro, J.E., Holman, P., Lane, T.A., Hassidim, K. & Ball, E.D. (2006) Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. Leukemia Research, 30, 503-506.
2. Braess, J., Wegendt, C., Jahns-Streubel, G., Kern, W., Keye, S., Unterhalt, M., Schleyer, E. & Hiddemann, W. (2000) Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine. British Journal of Haematology, 109, 388-395.
3. Braess, J., Jahns-Streubel, G., Schoch, C., Haase, D., Haferlach, T., Fiegl, M., Voss, S., Kern, W., Schleyer, E. & Hiddemann, W. (2001) Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. British Journal of Haematology, 113, 975-982.
4. Breems, D.A., Van Putten, W.L., Huijgens, P.C., Ossenkoppele, G.J., Verhoef, G.E., Verdonck, L.F., Vellenga, E., De Greef, G.E., Jacky, E., Van der Lelie, J., Boogaerts, M.A. & Löwenberg, B. (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 23, 1969-1978.
5. Burnett, A.K., Russell, N.H., Kell, J., Dennis, M., Milligan, D., Paolini, S., Yin, J., Culligan, D., Johnston, P., Murphy, J., McMullin, M.F., Hunter, A., Das-Gupta, E., Clark, R., Carr, R. & Hills, R.K. (2010) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. Journal of Clinical Oncology, 28, 2389-2395.
6. Carella, A.M., Cascavilla, N., Greco, M.M., Melillo, L., Sajeva, M.R., Ladogana, S., D'Arena, G., Perla, G. & Carotenuto, M. (2001) Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leukemia Lymphoma, 40, 295-303.
7. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Löwenberg, B., Sanz, M.A., Head, D.R., Ohno, R., Bloomfield, C.D. & International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Journal of Clinical Oncology, 21, 4642-4649.
8. Cooper, T., Ayres, M., Nowak, B. & Gandhi, V. (2005) Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemotherapy and Pharmacology, 55, 361-368.
9. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., Yver, A., Degos, L. & for the AML Cooperative Study Group (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. New England Journal of Medicine, 332, 1678-1683.
10. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C., Kornblau, S., Pierce, S., Freireich, E.J., Deisseroth, A. & Keating, M. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology, 12, 671-678.
11. Estey, E., Kornblau, S., Pierce, S., Kantarjian, H., Beran, M. & Keating, M. (1996) A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood, 88, 756.
12. Estey, E.H., Thall, P.F., Pierce, S., Cortes, J., Beran, M., Kantarjian, H., Keating, M.J., Andreeff, M. & Freireich, E. (1999) Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood, 93, 2478-2484.
13. Faderl, S., Gandhi, V., O'Brien, S., Bonate, P., Cortes, J., Estey, E., Beran, M., Wierda, W., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Giles, F.J., Du, M., Kwari, M., Keating, M., Plunkett, W. & Kantarjian, H. (2005) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood, 105, 940-947.
14. Faderl, S., Verstovsek, S., Cortes, J., Ravandi, F., Beran, M., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., O'Brien, S., Koller, C., Giles, F.J., Wierda, W., Kwari, M. & Kantarjian, H.M. (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50years of age or older. Blood, 108, 45-51.
15. Faderl, S., Ravandi, F., Huang, X., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Borthakur, G., Verstovsek, S., Thomas, D.A., Kwari, M. & Kantarjian, H.M. (2008) A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 112, 1638-1645.
16. Faderl, S., Wetzler, M., Rizzieri, D., Schiller, G.J., Jagasia, M.H., Stuart, R.K., Ganguly, S., Avigan, D., Craig, M., Collins, R., Maris, M.B., Kovacsovics, T., Goldberg, S., Seiter, K., Hari, P., Ravandi, F., Wang, E.S., Eckert, S., Huebner, D. & Kantarjian, H. (2011) Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): results from the phase III CLASSIC 1 trial. Journal of Clinical Oncology, 29, 2011.
17. Fernandez, H.F., Sun, Z., Yao, X., Litzow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G.W., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M. & Tallman, M.S. (2009) Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine, 361, 1249-1259.
18. Ferrara, F., Palmieri, S., Pocali, B., Pollio, F., Viola, A., Annunziata, S., Sebastio, L., Schiavone, E.M., Mele, G., Gianfaldoni, G. & Leoni, F. (2002) De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). European Journal of Haematoogy, 68, 203-209.
19. Godwin, J.E., Kopecky, K.J., Head, D.R., Willman, C.L., Leith, C.P., Hynes, H.E., Balcerzak, S.P. & Appelbaum, F.R. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood, 91, 3607-3615.
20. Heil, G., Hoelzer, D., Sanz, M.A., Lechner, K., Liu Yin, J.A., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., Matcham, J. & Barge, A. (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood, 90, 4710-4718.
21. Hofmann, W.K., Heil, G., Zander, C., Wiebe, S., Ottmann, O.G., Bergmann, L., Hoeffken, K., Fischer, J.T., Knuth, A., Kolbe, K., Schmoll, H.J., Langer, W., Westerhausen, M., Koelbel, C.B., Hoelzer, D. & Ganser, A. (2004) Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Annals of Hematology, 83, 498-503.
22. Jackson, G., Taylor, P., Smith, G.M., Marcus, R., Smith, A., Chu, P., Littlewood, T.J., Duncombe, A., Hutchinson, M., Mehta, A.B., Johnson, S.A., Carey, P., MacKie, M.J., Ganly, P.S., Turner, G.E., Deane, M., Schey, S., Brookes, J., Tollerfield, S.M. & Wilson, M.P. (2001) A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. British Journal of Haematology, 112, 127-137.
23. Kern, W., Aul, C., Maschmeyer, G., Kuse, R., Kerkhoff, A., Grote-Metke, A., Eimermacher, H., Kubica, U., Wörmann, B., Büchner, T. & Hiddemann, W. (1998) Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group. Annals of Hematology, 77, 115-122.
24. Löwenberg, B., van Putten, W., Theobald, M., Gmür, J., Verdonck, L., Sonneveld, P., Fey, M., Schouten, H., de Greef, G., Ferrant, A., Kovacsovics, T., Gratwohl, A., Daenen, S., Huijgens, P., Boogaerts, M., Dutch-Belgian Hemato-Oncology Cooperative Group & Swiss Group for Clinical Cancer Research. (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. New England Journal of Medicine, 349, 743-752.
25. Ohno, R., Naoe, T., Kanamaru, A., Yoshida, M., Hiraoka, A., Kobayashi, T., Takanori, U., Minami, S., Morishima, Y., Saito, Y., Furusawa, S., Imai, K., Takemoto, Y., Miura, Y., Teshima, H., Hamajima, N. & the Kohseisho Leukemia Study Group. (1994) A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood, 83, 2086-2092.
26. Ossenkoppele, G.J., Graveland, W.J., Sonneveld, P., Daenen, S.M., Biesma, D.H., Verdonck, L.F., Schaafsma, M.R., Westveer, P.H., Peters, G.J., Noordhuis, P., Muus, P., Selleslag, D., van der Holt, B., Delforge, M., Löwenberg, B., Verhoef, G.E. & Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). (2004) The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood, 103, 2908-2913.
27. Parker, W.B., Shaddix, S.C., Chang, C.H., White, E.L., Rose, L.M., Brockman, R.W., Shortnacy, A.T., Montgomery, J.A., Secrist, J.A. 3rd & Bennett, L.L. Jr (1991) Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Research, 51, 2386-2394.
28. Powell, B., D'Agostino, R., Levitan, D., Ellis, L., Lyerly, S., Skiles, M., Manuel, M., Harrelson, R., Kimbrough, C. & Hurd, D.D. (2008) High dose cytarabine and clofarabine (HiDAC CLOF) in relapsed or refractory acute myeloid leukemia; a phase 2 trial [abstract]. Blood, 112, 1936.
29. Pulte, D., Gondos, A. & Brenner, H. (2010) Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Annals of Oncology, 21, 335-341.
30. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 96, 4075-4083.
31. Thomas, X., Raffoux, E., Renneville, A., Pautas, C., de Botton, S., Terre, C., Gardin, C., Hayette, S., Preudhomme, C. & Dombret, H. (2010) Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study Cancer, 116, 1725-1732.
32. Visani, G., Tosi, P., Zinzani, P.L., Manfroi, S., Ottaviani, E., Testoni, N., Clavio, M., Cenacchi, A., Gamberim, B., Carrara, P., Gobbi, M. & Tura, S. (1994) FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia, 8, 1842-1846.
33. Walter, R.B., Othus, M., Borthakur, G., Ravandi, F., Cortes, J.E., Pierce, S.A., Appelbaum, F.R., Kantarjian, H. & Estey, E.H. (2010) Quantitative effect of age in predicting empirically-defined treatment-related mortality and resistance in newly diagnosed AML: case against age alone as primary determinant of treatment assignment. Blood, 116, Abstract 2191.
34. Xie, K.C. & Plunkett, W. (1996) Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Research, 56, 3030-3037.